Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

BACKGROUND: Dapagliflozin, a novel inhibitor of sodium-glucose cotransporter-2 (SGLT-2), lowers blood glucose level by specifically inhibiting the activity of SGLT-2. Previous studies showed efficacy and safety of dapagliflozin combined with other antihyperglycemic agents in type 2 diabetes (T2DM),...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Miao, Lv, Haihong, Xu, Xia, Wang, Jue, Lyu, Wenyi, Fu, Songbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709066/
https://www.ncbi.nlm.nih.gov/pubmed/31348290
http://dx.doi.org/10.1097/MD.0000000000016575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709066/
https://www.ncbi.nlm.nih.gov/pubmed/31348290
http://dx.doi.org/10.1097/MD.0000000000016575

Ejemplares similares